4/2/2013

The Pharmaceutical Research and Manufacturers of America rebuked India's Supreme Court for refusing to grant Novartis patent protection on its cancer medicine Glivec. The ruling is "another example of what I would characterize as a deteriorating innovation environment in India," said Chip Davis, PhRMA's executive vice president of advocacy. "[I]t is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide," PhRMA CEO John J. Castellani said.

Related Summaries